采用重组人血小板生成素和重组人白细胞介素11治疗血小板减少症的临床疗效比较
|
摘要
目的采用重组人血小板生成素和重组人白细胞介素11治疗血小板减少症的临床疗效比较。方法选择我院于2016年10月～2018年11月收治的70例血小板减少症患者作为研究对象,采用随机数字表法平均分为对照组和实验组,每组各35例。对照组患者采用重组人白细胞介素11治疗,实验组患者采用重组人血小板生成素治疗。对比两种治疗方案对血小板相关指标、不良反应发生率、T淋巴细胞亚群变化情况、治疗总有效率的影响。结果治疗后,实验组患者血小板相关指标、T淋巴细胞亚群水平明显优于对照组,差异有统计学意义(P<0.05);实验组患者总不良反应率8.6%,明显低于对照组总不良反应率为37.1%,差异具有统计学意义(x~2=8.102,P=0.004);实验组治疗总有效率为97.1%,明显高于对照组总有效率80%,差异具有统计学意义(P<0.05)。结论血小板减少症采用重组人血小板生成素治疗具有更高的临床疗效,更进一步改善血小板相关指标及T淋巴细胞亚群水平,且不良反应少,安全性较高,值得临床推广应用。
Objective This study aimed to analyze the effect of recombinant human thrombopoietin and recombinant human interleukin 11 in thrombocytopenia. Methods A total of 70 patients with thrombocytopenia in our hospital from October 2016. to November 2018, were divided into the control group and the experimental group, with 35 cases in each group. The control group was treated with recombinant human interleukin 11 and the experimental group was treated with recombinant human thrombopoietin. The effects of the two treatment regimens on platelet-related indicators, incidence of adverse reactions, changes in T lymphocyte subsets, and total effective rate of treatment were compared. Results Compared with the control group, the platelet-related index and T lymphocyte subsets were superior in the experimental group(P<0.05). The incidence of adverse reactions was lower than that in the control group(P<0.05); the total effective rate of treatment compared with the control group, the experimental group was higher, statistically significant(P<0.05). Conclusion Thrombocytopenia has certain clinical effects with recombinant human thrombopoietin and recombinant human interleukin-11, but recombinant human thrombopoietin is superior to recombinant human interleukin 11, especially in platelet-related indicators and T. Lymphocyte subsets have certain advantages, and have fewer adverse reactions and higher safety, which is worthy of clinical application.
Objective This study aimed to analyze the effect of recombinant human thrombopoietin and recombinant human interleukin 11 in thrombocytopenia. Methods A total of 70 patients with thrombocytopenia in our hospital from October 2016. to November 2018, were divided into the control group and the experimental group, with 35 cases in each group. The control group was treated with recombinant human interleukin 11 and the experimental group was treated with recombinant human thrombopoietin. The effects of the two treatment regimens on platelet-related indicators, incidence of adverse reactions, changes in T lymphocyte subsets, and total effective rate of treatment were compared. Results Compared with the control group, the platelet-related index and T lymphocyte subsets were superior in the experimental group(P<0.05). The incidence of adverse reactions was lower than that in the control group(P<0.05); the total effective rate of treatment compared with the control group, the experimental group was higher, statistically significant(P<0.05). Conclusion Thrombocytopenia has certain clinical effects with recombinant human thrombopoietin and recombinant human interleukin-11, but recombinant human thrombopoietin is superior to recombinant human interleukin 11, especially in platelet-related indicators and T. Lymphocyte subsets have certain advantages, and have fewer adverse reactions and higher safety, which is worthy of clinical application.
引文
[1]谢英丽,王小路,葛仁英.健脾益气摄血方联合重组人血小板生成素治疗脾气虚型免疫性血小板减少症疗效及对患者疲劳状况的影响[J].现代中西医结合杂志,2018,27(33):3696-3699.
[2]朱玲玲,张彦,陈光,等.重组人血小板生成素、地塞米松联合疗法治疗原发性免疫性血小板减少症的疗效及对T淋巴细胞亚群的影响[J].中国现代医生,2018,56(23):33-35.
[3]陈莹,刘思艺,王蓉,等.重组人白细胞介素-11治疗化疗后血小板减少症疗效与安全性[J].中国临床药理学杂志,2017,33(18):1817-1819;1846.
[4]安志丹.重组人白细胞介素-11联合糖皮质激素治疗初治免疫性血小板减少症的疗效及安全性[J].临床医学,2017,37(05):53-55.
[5]李江华.重组人白细胞介素-11对化疗后血小板减少症的治疗作用分析[J].中国现代药物应用,2017,11(04):66-67.
[6]张江霞,肖正红.重组人血小板生成素联合重组人白细胞介素11治疗恶性肿瘤放化疗后血小板减小症的安全性及有效性[J].医学综述,2016,22(15):3059-3063.
[7]任天舒,张岩,曲佳鑫,等.重组人血小板生成素与重组人白细胞介素11治疗血小板减少症疗效与安全性的Meta分析[J].药物流行病学杂志,2016,25(01):6-10.
[8]赖寒,杨红艳.重组人白细胞介素-11治疗实体瘤化疗致血小板减少症的随机对照研究[J].深圳中西医结合杂志,2014,24(06):68-69.
[2]朱玲玲,张彦,陈光,等.重组人血小板生成素、地塞米松联合疗法治疗原发性免疫性血小板减少症的疗效及对T淋巴细胞亚群的影响[J].中国现代医生,2018,56(23):33-35.
[3]陈莹,刘思艺,王蓉,等.重组人白细胞介素-11治疗化疗后血小板减少症疗效与安全性[J].中国临床药理学杂志,2017,33(18):1817-1819;1846.
[4]安志丹.重组人白细胞介素-11联合糖皮质激素治疗初治免疫性血小板减少症的疗效及安全性[J].临床医学,2017,37(05):53-55.
[5]李江华.重组人白细胞介素-11对化疗后血小板减少症的治疗作用分析[J].中国现代药物应用,2017,11(04):66-67.
[6]张江霞,肖正红.重组人血小板生成素联合重组人白细胞介素11治疗恶性肿瘤放化疗后血小板减小症的安全性及有效性[J].医学综述,2016,22(15):3059-3063.
[7]任天舒,张岩,曲佳鑫,等.重组人血小板生成素与重组人白细胞介素11治疗血小板减少症疗效与安全性的Meta分析[J].药物流行病学杂志,2016,25(01):6-10.
[8]赖寒,杨红艳.重组人白细胞介素-11治疗实体瘤化疗致血小板减少症的随机对照研究[J].深圳中西医结合杂志,2014,24(06):68-69.